ArQule (ARQL) Stock: Rocketing On Clinical Data

ArQule ARQL Stock News

ArQule, Inc. (NASDAQ: ARQL) is having a great start to the trading session this morning, and for good reason. The company announced preliminary results from an ongoing Phase 1 study. Of course, the results were positive, exciting investors and sending the stock for the top. Today, we’ll talk about: The clinical data; what we’re seeing … Read more

La Jolla Pharmaceutical (LJPC) Stock: Continuing Its Run For The Top

La Jolla Pharmaceutical Company LJPC Stock News

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is climbing in the market yet again today, following up on the incredible gains that the stock saw yesterday. The gains follow the company’s announcement surrounding clinical data, which led to nearly 100% gains yesterday, followed by 20% gains today in the premarket. LJPC Stock Gains On Clinical Data … Read more

Actinium Pharmaceuticals (ATNM) Stock: Climbing On New Pivotal Data

Actinium Pharmaceuticals ATNM Stock News

Actinium Pharmaceuticals Inc (NYSEAMERICAN: ATNM) is headed up early on in the trading session with gains of more than 6% just after the opening bell. The gains come for good reason too. In a press release, the company said that it presented new pivotal Phase 3 data and provided a look at the data, which … Read more

Genocea Biosciences (GNCA) Stock: Cancer Vaccine Data Leads To Gains

Genocea Biosciences GNCA Stock News

Genocea Biosciences Inc (NASDAQ: GNCA) is grabbing the attention of investors this morning after announcing data from an early-stage clinical trial assessing a cancer vaccine. The data proved to be positive, leadint to excitement among investors and gains of more than 70% early in today’s trading session. Stop wasting your time! Start finding winning trades … Read more

Cara Therapeutics (CARA) Stock: Flying On Clinical Data

Cara Therapeutics CARA Stock News

Cara Therapeutics Inc (NASDAQ: CARA) is having an incredibly strong start to the trading session this morning, and for good reason. The company released clinical results, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The clinical data; what we’re seeing from CARA stock as a result; and what we’ll … Read more

Armata Pharmaceuticals (ARMP) Stock: Up Big On Clinical Data Publication

Armata Pharmaceuticals ARMP Stock News

Armata Pharmaceuticals Inc (NYSEAMERICAN: ARMP) is climbing in the market this morning, and for good reason. The company announced the publication of positive clinical data, exciting investors and sending the stock running for the top. Today, we’ll talk about: The data presentation; what we’re seeing from ARMP stock as a result; and what we’ll be … Read more

Neovasc (NVCN) Stock: Climbing On Data Publication

Neovasc NVCN Stock News

Neovasc Inc (NASDAQ: NVCN) is seeing overwhelming gains in value early this morning, and for good reason. In the afterhours session yesterday, the comapny announced new data surrounding its Reducer product. Today, we’ll talk about: The data; what we’re seeing from NVCN stock as a result; and what we’ll be watching for ahead. NVCN Gains … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Falling Hard After Positive Study Results

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is having an overwhelmingly rough start in the premarket hours this morning, leaving many wondering why. The company released what it said was positive clinical data from a Phase 3 trial. However, reading between the lines shows us that things aren’t always what they seem. Today, we’ll talk about: The … Read more

Achillion Pharmaceuticals (ACHN) Stock: Climbing On Clinical Data

Achillion Pharmaceuticals ACHN Stock News

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced positive clinical data, exciting investors and sending the stock for the top. Today, we’ll talk about: The data; what we’re seeing from ACHN stock as a result; and what we’ll be … Read more

Cellectar Biosciences (CLRB) Stock: Gaining On CLR 131 Update

Cellectar Biosciences CLRB Stock News

Cellectar Biosciences Inc (NASDAQ: CLRB) is having an incredibly strong start to the trading session this morning, and for good reason. The company provided an update with regard to its lead candidate, CLR 131. Of course, the update excited investors, pushing the stock up. Today, we’ll talk about: The CLR 131 update; what we’re seeing … Read more